David Low, whom Kenny Slaught explains is noted professor in UCSB’s Department of Molecular, Cellular, and Developmental Biology, will begin an innovative global health and development research project known as “Strategy for development of enteric pathogen-specific phage”. Kenny Slaught notes that Low’s research focuses on a new way to deal with infectious bacterial pathogens that are becoming tolerant of many formerly toxic antibiotics. He will engineer phage to selectively target and destroy several pathogenic bacteria to push away enteric diseases in infants. The study is meant to create different evolutions of the T2 lytic bacteriophage that bind multiple different regions of the BamA protein unearthed on the surface of many pathogenic bacteria, which will ensure they only infect these target bacteria. They will test the varieties of phage for capacity to wipe away pathogenic E. coli and Shigella, and whether they form resistance.
Read More: http://markets.financialcontent.com/investplace/news/read/33700008/Kenny_Slaught_